| Literature DB >> 32616502 |
Foteinos-Ioannis D Dimitrakopoulos1, Anastasia E Kottorou1, Melpomeni Kalofonou2, Haralabos P Kalofonos3.
Abstract
Thirty-four years since its discovery, NF-κB remains a transcription factor with great potential for cancer therapy. However, NF-κB-targeted therapies have yet to find a way to be clinically translatable. Here, we focus exclusively on the role of NF-κB in non-small cell lung cancer (NSCLC) and discuss its contributing effect on cancer hallmarks such as inflammation, proliferation, survival, apoptosis, angiogenesis, epithelial-mesenchymal transition, metastasis, stemness, metabolism, and therapy resistance. In addition, we present our current knowledge of the clinical significance of NF-κB and its involvement in the treatment of patients with NSCLC with chemotherapy, targeted therapies, and immunotherapy. ©2020 American Association for Cancer Research.Entities:
Year: 2020 PMID: 32616502 DOI: 10.1158/0008-5472.CAN-19-3578
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701